Cenovus Energy's Lima, Ohio, Refinery Flaring, but No Fire Event — OPIS
After industry talk of a fire at Cenovus Energy's Lima, Ohio, refinery, the company issued a news release Tuesday afternoon saying that there was no fire, but the facility was experiencing "issue" and additional flaring is being monitored.
The company said that all workers have been accounted for with no injuries, and as the refinery responds, local observers will see larger than normal flaring.
The region is nervous, with ExxonMobil's Joliet, Ill., refinery down and with an FCC down at Cenovus' Toledo refinery. Chicago-sourced reformulated gasoline still fetches 18cts/gal above CME RBOB, giving it temporary status as the most expensive gasoline in the country. Chicago CBOB rallied more than 6cts/gal to about $2.375/gal but it was not clear if it moved on the erroneous reports of a fire.
This content was created by Oil Price Information Service, which is operated by Dow Jones & Co. OPIS is run independently from Dow Jones Newswires and The Wall Street Journal.
--Reporting by Tom Kloza, tkloza@opisnet.com; Editing by Michael Kelly, mkelly@opisnet.com
(END) Dow Jones Newswires
July 30, 2024 18:04 ET (22:04 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks